Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up 545 million euros ($626 ...

Below is Validea's guru fundamental report for STRYKER CORP (SYK). Of the 22 guru strategies we follow, SYK rates highest using our Multi-Factor Investor model based on the published strategy of ...

Formation Bio’s subsidiary, Libertas Bio, has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi.

Investors in Stryker Corp (Symbol: SYK) saw new options become available today, for the August 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SYK ...

America’s new approach to enforcing a decades-old law outlawing foreign bribery means fresh risk for Canadian multinationals, ...

Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company ...

Investing.com -- Moody’s Ratings upgraded Stryker Corporation (NYSE: SYK )’s senior unsecured notes to A3 from Baa1 on Wednesday, while revising the company’s outlook to stable from positive.

Wellington motorists are being told to expect delays heading into the city this morning after a crash where two main ...